Strategic partner Volpara Health to distribute RevealAI-Lung™ in Australia and New Zealand
Wellington, NZ, 21 September 2022: RevealDx and Volpara Health (ASX: VHT) today announced that RevealAI-Lung™, an AI-powered software application that helps accelerate lung cancer diagnosis and reduce unnecessary procedures, has received Therapeutic Goods Administration (TGA) clearance from the Australian Government Department of Health. RevealAI-Lung will be sold in Australia and New Zealand by Volpara Health. Read more here.